A piece of news that just came out told us, it seems to be moving in this direction. AstraZeneca was supposed to be the workhorse of the EU's vaccine market this year, but unfavorable situations are emerging. As emergence of rare blood clots in some recipients, Denmark decided Wednesday not to use AstraZeneca's vaccine, that to exacerbate the problems for AstraZeneca.
According to ABC, the EU said that AstraZeneca promised to deliver 120 million doses for the 1st quarter, but only 30 million, the 180 million expected for the 2nd quarter, and now only 70 million were delivered, a huge shortfall has emerged.
EU Commission President Ursula von der Leyen said on Wednesday that America's Pfizer and Germany's BioNTech will provide the EU with an extra 50 million doses in the 2nd quarter of this year, making up for deliveries of AstraZeneca. Pfizer-BioNTech has previously already earmarked 200 million doses for the EU.
Currently, more and more countries have confidence about the technology was used by the Pfizer-BioNTech vaccine, it is different from that behind the Oxford-AstraZeneca vaccine. But anyway, Pfizer-BioNTech vaccine is marching towards the EU, and maybe we will see another scene in the EU in a few months.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.